6.1 The Committee was mindful of the circumstances of the patient population included in the evaluation, who are at high risk of venous thromboembolism and unable to receive either any other mechanical or pharmacological method of prophylaxis. It considered that it is plausible that the geko device would reduce the risk of venous thromboembolism in these patients, despite the lack of direct evidence from clinical studies. It also took account of the low risk of harm from the device. Taking these considerations into account, the Committee judged that the case for adoption of the geko device in this population of patients was supported.
6.2 The Committee considered that further research on the geko device in clinical settings could focus on reducing the current uncertainties about the reduction in relative risk in the defined patient population, and allow investigation into its use in broader patient populations.
Sir Andrew Dillon